semaglutide conversion to tirzepatide Switching conversion chart semaglutide to tirzepatide

The cardiovascular benefits of semaglutide extend beyond cholesterol management, contributing to better long-term health outcomes

[DOI] [PMC free article] [PubMed] [Google Scholar] 140.Freckmann G, Pleus S, Grady M, Setford S

Decreasing the dosage under guidance is best to manage these effects effectively

And here Zepbound holds an unfortunate special position: with an average of minus 20.9% on 15 mg in SURMOUNT-1, up to minus 22.5% over a longer course and even minus 26.6% in SURMOUNT-3, it achieves the greatest weight loss of any weight-management medicine approved in the US

In a clinical trial called SUSTAIN-6, Semaglutide was shown to significantly reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in individuals with type 2 diabetes who were at high risk for cardiovascular disease

Weight reduction through bariatric surgery or pharmacotherapy has been associated with lower DR risk [78]